BAM
SION

Bosun Asset Management’s Sionna Therapeutics SION Stock Holding History

Bosun Asset Management’s Portfolio SION Stock Details SION Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-16,975
Closed -$295K – 198
2025
Q2 		$295K Buy
+16,975
New +$222K 0.09% 173

Other funds holding SION

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Bosun Asset Management's SION Position: Q3 2025 in Review

Bosun Asset Management sold out of Sionna Therapeutics (SION) in Q3 2025, closing a stake of 16,975 shares — an estimated $295K sold.

Bosun Asset Management first reported a position in SION in Q2 2025 and held it in 1 quarter. The position peaked at $295K in Q2 2025. 78 funds tracked by Wall St. Rank hold SION as of Q3 2025.

  • Bosun Asset Management reported no remaining Sionna Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Bosun Asset Management sold 16,975 Sionna Therapeutics shares in Q3 2025, an estimated $295K.
  • Bosun Asset Management first reported a position in Sionna Therapeutics in Q2 2025 and held it in 1 quarter.
  • Bosun Asset Management's Sionna Therapeutics position peaked at $295K in Q2 2025.
  • 78 funds tracked by Wall St. Rank held Sionna Therapeutics as of Q3 2025.

Based on Bosun Asset Management's 13F filing for Q3 2025, filed 10 Nov 2025.